The diabetes surgery summit consensus conference: Recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus

Annals of Surgery

Volumn 251, Issue 3, 2010, Pages 399-405

  Rubino, Francesco ^a,b   Kaplan, Lee M ^c   Schauer, Philip R ^d   Cummings, David E ^e  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARIATRIC SURGERY; BODY MASS; CONFERENCE PAPER; DIABETES CONTROL; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GASTRECTOMY; HUMAN; MEDICAL SOCIETY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS;

EID: 77649149288     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181be34e7     Document Type: Conference Paper

References (40)

1. Juliana C.N. Chan, Vasanti Malik, Weiping J, et al. Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology. JAMA 2009;301:2129-2140.
2. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab. 2003;29(4 pt 2):6S9-18.
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
4. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630-2633.
5. Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:21i-33i.
6. Reaven PD, Moritz TE, Schwenke DC, et al. Veterans Affairs Diabetes Trial. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009;58:2642-2648.
7. Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44:1118-1120. Available at: http://www.advancetrial.com/static/html/ healthcare/home.asp.
8. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-1737.
9. de Paula AL, Macedo AL, Prudente AS, et al. Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")-pilot study of a new operation. Surg Obes Relat Dis. 2006;2:464-467.
10. Ramos AC, Galvao Neto MP, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI 30 kg/m2 (LBMI). Obes Surg. 2009; 19: 307-312.
11. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-350; discussion 350-1332
12. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of Laparoscopic Roux-en-Y Gastric Bypass on type II Diabetes Mellitus. Ann Surg 2003; 238:467-485. (Pubitemid 38176385)
13. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-242.
14. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006; 244:741-749.
15. Thaler JP, Cummings DE Hormonal mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150:2518-2525.
16. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761.
17. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752.
18. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr. 1992; 55(suppl 2):615S-619S.
19. MacDonald KG Jr. Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity. Arch Surg. 2003;138:357-360.
20. Rubino F, Schauer PR, Kaplan, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010; In Press.
21. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-323.
22. Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621-632; discussion 632-635.
23. Khuri S, Najjar S, Daley J, et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg. 2001;234:370-382; discussion 382-383.
24. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results, with 3-60 month follow-up. Obes Surg. 2000;10:233-239.
25. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes of laparoscopic Rous-en-Y gastric Bypass for morbid obesity. Ann Surg. 2000;232:515-529.
26. Nguyen NT, Hinojosa M, Fayad C, et al. Use and outcomes of laparoscopic versus open gastric bypass at academic medical centers. J Am Coll Surg. 2007;205:248-255.
27. Brolin R, LaMarca L, Kenler H, et al. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg. 2002;6:195-203; discussion 204-205.
28. Bloomberg R, Fleishman A, Nalle J, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15: 145-154.
29. Brolin R, Gorman R, Milgrim L, et al. Multivitamin prophylaxis in prevention of post-gastric bypass vitamin and mineral deficiencies. Int J Obes. 1991;15:661-667.
30. Halverson J. Micronutrient deficiencies after gastric bypass for morbid obesity. Am Surg. 1986;52:594-598.
31. Hamoui N, Kim K, Anthone G, et al. The significance of elevated levels of parathyroid hormone in patients with morbid obesity before and after bariatric surgery. Arch Surg. 2003;138:891-897.
32. 2: a tailored approach. Surg Obes Relat Dis. 2006;2:401-404; discussion 404
33. Lee WJ, Wang W, Lee YC, et al. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI 35 and 35 kg/m2. J Gastrointest Surg. 2008;12:945-952.
34. 2: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195-197.
35. Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18:1077-1082.
36. Sarson DL, Scopinaro N, Bloom SR. Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes. 1981;5:471-480.
37. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007; 246:780-785.
38. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002; 346:1623-1630.
39. Rehfeld JF. A centenary of gastointestinal endocrinology. Horm Metab Res. 2004;36:735-741.
40. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(suppl 1):S13-S61.